Welcome to the new version of CaltechAUTHORS. Login is currently restricted to library staff. If you notice any issues, please email coda@library.caltech.edu
Published November 18, 2021 | Supplemental Material + Submitted + Published
Journal Article Open

CST does not evict elongating telomerase but prevents initiation by ssDNA binding

Abstract

The CST complex (CTC1-STN1-TEN1) has been shown to inhibit telomerase extension of the G-strand of telomeres and facilitate the switch to C-strand synthesis by DNA polymerase alpha-primase (pol α-primase). Recently the structure of human CST was solved by cryo-EM, allowing the design of mutant proteins defective in telomeric ssDNA binding and prompting the reexamination of CST inhibition of telomerase. The previous proposal that human CST inhibits telomerase by sequestration of the DNA primer was tested with a series of DNA-binding mutants of CST and modeled by a competitive binding simulation. The DNA-binding mutants had substantially reduced ability to inhibit telomerase, as predicted from their reduced affinity for telomeric DNA. These results provide strong support for the previous primer sequestration model. We then tested whether addition of CST to an ongoing processive telomerase reaction would terminate DNA extension. Pulse-chase telomerase reactions with addition of either wild-type CST or DNA-binding mutants showed that CST has no detectable ability to terminate ongoing telomerase extension in vitro. The same lack of inhibition was observed with or without pol α-primase bound to CST. These results suggest how the switch from telomerase extension to C-strand synthesis may occur.

Additional Information

© The Author(s) 2021. Published by Oxford University Press on behalf of Nucleic Acids Research. This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial License (https://creativecommons.org/licenses/by-nc/4.0/), which permits non-commercial re-use, distribution, and reproduction in any medium, provided the original work is properly cited. Received August 25, 2021; Revised September 29, 2021; Editorial Decision September 29, 2021; Accepted October 01, 2021. We thank D. Herschlag (Stanford U.) and J. Lingner (EPFL, Lausanne) for valuable discussions. We thank T. Nahreini for her excellent management of the Biochemistry Cell Culture Facility, CU Boulder. T.R.C. is an investigator of the Howard Hughes Medical Institute. Funding: National Institutes of Health [R00 GM131023 to C.L., R01 GM139274 to D.S.W.]; National Science Foundation [MCB 1716425 to D.S.W.]; M.T.C. was supported by the Biological Sciences Initiative funded by the University of Colorado Boulder; Howard Hughes Medical Institute through the Science Education Program. Funding for open access charge: Howard Hughes Medical Institute and the University of Colorado Boulder Open Access Fund. Conflict of interest statement. T.R.C. is a scientific advisor for Storm Therapeutics and Eikon Therapeutics.

Attached Files

Published - gkab942.pdf

Submitted - 2021.08.25.457677v1.full.pdf

Supplemental Material - gkab942_supplemental_file.pdf

Files

2021.08.25.457677v1.full.pdf
Files (62.0 MB)
Name Size Download all
md5:df270896f3c9ffc8a79cec26ce75850e
23.0 MB Preview Download
md5:a4f398d62685e6a305e37dc3b5d75a83
6.9 MB Preview Download
md5:539841bbcff85b3ad4165f599fc6594b
32.1 MB Preview Download

Additional details

Created:
August 20, 2023
Modified:
October 23, 2023